VYNE — Vyne Therapeutics Income Statement
0.000.00%
- $30.95m
- $11.88m
- $0.42m
- 12
- 31
- 23
- 11
Annual income statement for Vyne Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 21 | 0.931 | 0.477 | 0.424 |
Cost of Revenue | |||||
Gross Profit | — | 19.6 | — | — | — |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 76.2 | 274 | 39.8 | 34.8 | 29.7 |
Operating Profit | -76.2 | -253 | -38.9 | -34.3 | -29.3 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -73.7 | -256 | -44.7 | -33.9 | -27.9 |
Provision for Income Taxes | |||||
Net Income After Taxes | -73.7 | -256 | -44.2 | -33.9 | -27.9 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -73.7 | -256 | -73.3 | -23.2 | -28.5 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -73.7 | -256 | -73.3 | -23.2 | -28.5 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -223 | -142 | -15.5 | -10.7 | -2.71 |